FDA Holds Public Hearing on Biosimilar Draft Guidance

by McDonnell Boehnen Hulbert & Berghoff LLP

[author: James DeGiulio]

FDALast week, the U.S. Food and Drug Administration held a public hearing on the Draft Guidance on Biosimilar Development, where researchers, payors, patient and physician groups, and industry advocates provided their thoughts on the FDA's first attempt to clarify the logistics as to the operation of the Biologics Price Competition and Innovation Act of 2009 (BPCIA).  The panel was headed by Dr. Rachel Sherman, M.D., Associate Director for Medical Policy at CDER, and comprised other agency members Dr. Leah Christl, Ph.D.; Denise Esposito, J.D.; Dr. Steven Kozlowski, M.D.; Diane Maloney, J.D.; Heidi C. Marchand, PharmD; Maryll Toufanian, J.D.; and Robert A. Yetter, Ph.D.  The public hearing follows a 60 day period for comment, where the FDA dockets saw more than 44 different stakeholders represented.

With only eight minutes allotted, most of the speakers used their time to hit the key points of contention from their submitted comments.  As expected, innovator representatives advocated for more clinical studies and stricter standards for identity of products, but what was not expected was the strong support for this position from patient groups as well.  Indeed, patient advocacy groups seemed to be unconvinced that biosimilars would represent products that were just as effective and safe as the brand competitors.  While the groups want the price breaks the follow-on drugs might offer, they are far more concerned about safety, and want to see additional clinical trials.  Representatives from the National Kidney Foundation, Colon Cancer Alliance, and the Alliance for Safe Biologic Medicines warned that seemingly insignificant changes in manufacturing, packaging, handling, and storing of biologics can have unintended consequences that produce a drug that does not work or can be unsafe.

Biosimilar developer representatives used this opportunity to request resources from the FDA for patient education.  Representatives from Momenta focused the discussion on what is demanded in the statute:  clinical trials to establish biosimilarity to the reference product; there is no requirement to independently establish the safety and efficacy of the biosimilar product.  The FDA has stood fast on its position that human clinical trials should not be repeated.  Therefore, clinical trials on a product the FDA determines to be biosimilar could not be justified.  Proving biosimilarity represents an unconventional approach to drug approval.  Indeed, any argument suggesting that a drug's safety and efficacy do not need to be tested will cause unease from patient groups.  Patient advocates and physician groups stated that their constituents will need additional educational materials, including lay summaries of the Guidances, and are interested in interactive presentations from FDA on the appropriate use of these new products.  All of the stakeholders share support for the implementation of an education and communication plan to help the public and other entities understand biosimilars.  For example, the representative from the American Pharmacists Association said pharmacists are unaware of the proper process to follow when they start seeing prescriptions for biosimilar products.

All of the speakers agreed that the FDA should be commended for its scientific and safety-oriented approach in the draft guidance, which begin to pave the way to meeting the need to protect patient safety, encourage product innovation, and create meaningful cost-savings in the biosimilars field.  There were other points of substantive agreement at the hearing, which provides some level of optimism for the FDA's chances of establishing a working protocol for biosimilar approval.  Interestingly, it seems that industry players on both sides of the field are in favor of deferring to the EMA's guidances, which provide detailed guidance for biological products according to classes.  This would provide for harmonization with the rest of the world, as well as preserving FDA resources and speeding approvals.  Despite this supposed harmonization, innovator companies would not agree that referencing a non-US product should be permissible, as it is under the Draft Guidance in certain situations.  Abbott suggested that this was not permitted, citing the language of the statute noting a "single biological product" for biosimilar comparison -- not multiple biological products as would be required.

Stakeholders advocated changes to a wide variety of issues, but biosimilar naming was prominent throughout the hearing.  Patient groups and innovator representatives encouraged the FDA to require unique names for biosimilars, which would help hold manufacturers accountable for their products.  If a common nonproprietary name were used, patients wouldn't know which drug they're getting.  Advocates for a common name raised the possibility of overdosing or misdosing if different names were used, as a patient could inadvertently be prescribed two versions of the same biosimilar.  The FDA has voiced its intent to publish a future guidance on naming, as well as interchangeability, which may account for the extensive testimony on these two key issues, despite their minimal coverage in the Draft Guidance.

The panel was peppered with suggestions for how to improve the Draft Guidances, but few speakers had research available to support their proposed improvements.  For example, several speakers took issue with the FDA's definition of the term "protein," finding that the 40 amino acid cutoff is totally arbitrary.  While some speakers advocated for a more functional definition, such as peptides produced in a cell, the panel stood firm on this definition, emphasizing the need for a bright line rule dictating where polypeptides come under the exclusive coverage of the PHSA.  Without any evidence showing a problem with the current definition, the FDA noted that no matter which definition was chosen, someone would always find it to be arbitrary.  With several topics, the panel charged many of the speakers to support their testimony with additional commentary, including any research that can be located to support their proposed changes to the Guidance.  The panel encouraged these groups to submit their findings and other suggestions on implementation to the docket (FDA-2011-D-0618) at www.regulations.gov.  The FDA will continue to accept comments through May 25.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.